See more : iCetana Limited (ICE.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Swedish Orphan Biovitrum AB (publ) (SOBI.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Swedish Orphan Biovitrum AB (publ), a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Tetra Tech, Inc. (TTEK) Income Statement Analysis – Financial Results
- United Parcel Service, Inc. (UPAB.DE) Income Statement Analysis – Financial Results
- Vubotics, Inc. (VBTC) Income Statement Analysis – Financial Results
- Deva Holding A.S. (DEVA.IS) Income Statement Analysis – Financial Results
- Galenfeha, Inc. (GLFH) Income Statement Analysis – Financial Results
Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
About Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22.12B | 18.79B | 15.53B | 15.26B | 14.25B | 9.14B | 6.51B | 5.20B | 3.23B | 2.61B | 2.18B | 1.92B | 1.91B | 1.91B | 1.30B | 1.14B | 1.26B | 1.20B | 936.61M | 645.29M | 1.66B | 1.30B |
| Cost of Revenue | 5.00B | 4.78B | 3.48B | 3.23B | 3.34B | 2.42B | 1.85B | 1.55B | 1.22B | 1.06B | 892.73M | 882.78M | 936.26M | 685.70M | 375.74M | 264.66M | 348.77M | 293.81M | 270.66M | 248.32M | 611.98M | 596.87M |
| Gross Profit | 17.13B | 14.01B | 12.05B | 12.04B | 10.91B | 6.72B | 4.66B | 3.65B | 2.01B | 1.55B | 1.28B | 1.04B | 974.57M | 1.22B | 921.23M | 875.92M | 907.66M | 907.29M | 665.95M | 396.96M | 1.05B | 704.82M |
| Gross Profit Ratio | 77.42% | 74.58% | 77.56% | 78.87% | 76.59% | 73.57% | 71.52% | 70.14% | 62.17% | 59.37% | 58.99% | 54.10% | 51.00% | 64.04% | 71.03% | 76.80% | 72.24% | 75.54% | 71.10% | 61.52% | 63.08% | 54.15% |
| Research & Development | 2.80B | 2.35B | 1.99B | 1.59B | 1.50B | 1.09B | 907.72M | 777.59M | 513.37M | 500.49M | 455.69M | 401.65M | 555.72M | 479.80M | 569.42M | 670.56M | 694.35M | 650.35M | 576.00M | 534.70M | 583.17M | 568.73M |
| General & Administrative | 10.16B | 7.85B | 6.29B | 5.98B | 0.00 | 0.00 | 1.28M | 2.32M | 3.46M | 3.66M | 3.38M | 4.25M | 804.46M | 479.80M | 193.30M | 216.18M | 77.38M | 77.36M | 151.23M | 129.18M | 114.99M | 139.97M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 4.94B | 2.51B | 2.10B | 1.78B | 1.34B | 1.03B | 898.23M | 961.14M | 0.00 | 825.70M | 109.61M | 51.78M | 43.72M | 41.59M | 38.66M | 34.51M | 37.18M | 58.21M |
| SG&A | 10.16B | 7.85B | 6.29B | 5.98B | 4.94B | 2.51B | 2.10B | 1.78B | 1.35B | 1.04B | 901.60M | 965.39M | 804.46M | 1.31B | 302.90M | 267.96M | 121.10M | 118.95M | 189.90M | 163.69M | 152.16M | 198.17M |
| Other Expenses | 0.00 | -32.00M | -30.00M | -2.00M | -16.00M | -2.13M | 471.00K | 1.70M | 236.00K | 781.00K | 2.73M | 8.84M | -197.08M | -641.80M | 76.00M | -380.10M | 1.03M | 266.00K | -402.49M | 23.28M | -393.65M | 22.67M |
| Operating Expenses | 13.06B | 10.17B | 8.26B | 7.57B | 6.41B | 3.60B | 3.01B | 2.55B | 1.86B | 1.53B | 1.36B | 1.36B | 1.16B | 1.14B | 948.32M | 11.73M | 850.49M | 802.81M | 393.38M | 339.54M | 985.56M | 660.71M |
| Cost & Expenses | 18.06B | 14.95B | 11.74B | 10.80B | 9.75B | 6.01B | 4.86B | 4.11B | 3.08B | 2.59B | 2.25B | 2.24B | 2.10B | 1.83B | 1.32B | 276.40M | 1.20B | 1.10B | 664.05M | 587.86M | 1.60B | 1.26B |
| Interest Income | 27.00M | 5.00M | 419.00M | 1.00M | 5.00M | 2.74M | 1.22M | 1.43M | 2.93M | 4.23M | 4.49M | 2.33M | 10.50M | 4.73M | 28.60M | 1.22M | 3.01M | 2.37M | 1.58M | 358.00K | 924.00K | 8.32M |
| Interest Expense | 1.11B | 458.00M | 419.00M | 454.00M | 241.00M | 56.46M | 63.97M | 78.55M | 54.71M | 56.62M | 60.41M | 42.25M | 62.73M | 77.44M | 12.34M | 21.42M | 450.00K | 262.00K | 49.43M | 52.22M | 36.84M | 39.26M |
| Depreciation & Amortization | 3.17B | 2.27B | 2.00B | 2.02B | 1.51B | 484.57M | 473.98M | 440.71M | 318.99M | 581.55M | 307.62M | 454.30M | 140.59M | 175.40M | 28.60M | -378.88M | 70.49M | 74.54M | -400.92M | 23.63M | -392.72M | 30.99M |
| EBITDA | 7.23B | 6.05B | 5.71B | 6.73B | 6.02B | 3.63B | 2.07B | 1.58B | 462.31M | 51.58M | 241.95M | 391.45M | -46.91M | 165.20M | 44.78M | -364.78M | 141.56M | 168.99M | -128.35M | 81.06M | -332.89M | 75.10M |
| EBITDA Ratio | 32.70% | 32.99% | 37.19% | 41.26% | 42.41% | 39.64% | 31.98% | 30.03% | 14.29% | 25.69% | 11.04% | 6.30% | -9.32% | 8.66% | 3.45% | -30.21% | 12.37% | 17.76% | -13.70% | 12.56% | -20.09% | 5.77% |
| Operating Income | 4.66B | 3.81B | 3.73B | 4.82B | 4.53B | 3.12B | 1.60B | 1.13B | 146.04M | -324.98M | -66.53M | -54.61M | -318.62M | -10.20M | 16.17M | 34.30M | 55.12M | 54.59M | 272.56M | 57.43M | 59.84M | 44.11M |
| Operating Income Ratio | 21.05% | 20.29% | 24.04% | 31.57% | 31.81% | 34.16% | 24.58% | 21.77% | 4.52% | -12.47% | -3.06% | -2.84% | -16.67% | -0.53% | 1.25% | 3.01% | 4.39% | 4.54% | 29.10% | 8.90% | 3.61% | 3.39% |
| Total Other Income/Expenses | -1.70B | -492.00M | -438.00M | -601.00M | -286.00M | -40.00M | -73.69M | -85.14M | -61.31M | -336.58M | -56.88M | -24.97M | -52.23M | -82.24M | 16.30M | -400.30M | 23.87M | -40.95M | -450.35M | -28.59M | -429.57M | -8.27M |
| Income Before Tax | 2.95B | 3.32B | 3.30B | 4.22B | 4.25B | 3.08B | 1.53B | 1.05B | 87.69M | -318.57M | -123.42M | -105.09M | -370.85M | -92.40M | 32.44M | -366.00M | 78.99M | 94.19M | -177.78M | 28.84M | -369.73M | 35.84M |
| Income Before Tax Ratio | 13.35% | 17.67% | 21.22% | 27.63% | 29.81% | 33.72% | 23.54% | 20.14% | 2.72% | -12.22% | -5.67% | -5.46% | -19.41% | -4.85% | 2.50% | -32.09% | 6.29% | 7.84% | -18.98% | 4.47% | -22.31% | 2.75% |
| Income Tax Expense | 546.00M | 683.00M | 616.00M | 972.00M | 942.00M | 663.94M | 383.81M | 238.91M | 19.30M | -50.73M | -30.46M | -4.21M | -388.77M | 12.00M | 43.26M | -30.64M | 1.00K | 1.52M | 1.00M | -2.35M | -739.46M | 1.00K |
| Net Income | 2.41B | 2.64B | 2.68B | 3.25B | 3.30B | 2.42B | 1.15B | 809.07M | 68.39M | -267.83M | -92.96M | -100.88M | 17.93M | -104.40M | 32.44M | -335.36M | 78.98M | 92.67M | 176.22M | -26.49M | 369.73M | -35.85M |
| Net Income Ratio | 10.89% | 14.04% | 17.25% | 21.26% | 23.19% | 26.46% | 17.64% | 15.55% | 2.12% | -10.27% | -4.27% | -5.25% | 0.94% | -5.48% | 2.50% | -29.40% | 6.29% | 7.72% | 18.81% | -4.11% | 22.31% | -2.75% |
| EPS | 7.47 | 8.52 | 8.67 | 10.52 | 10.78 | 8.93 | 4.27 | 2.99 | 0.24 | -1.01 | -0.35 | -0.38 | 0.07 | -0.53 | 0.29 | -3.00 | 0.78 | 0.90 | 1.73 | -0.26 | 3.63 | -0.35 |
| EPS Diluted | 7.39 | 8.44 | 8.62 | 10.41 | 10.72 | 8.93 | 4.25 | 2.98 | 0.24 | -1.01 | -0.35 | -0.38 | 0.07 | -0.52 | 0.29 | -3.00 | 0.76 | 0.83 | 1.73 | -0.26 | 3.63 | -0.35 |
| Weighted Avg Shares Out | 322.66M | 309.48M | 308.90M | 308.49M | 306.38M | 270.60M | 269.02M | 268.36M | 267.28M | 265.18M | 265.27M | 265.23M | 242.12M | 198.74M | 56.42M | 111.91M | 101.82M | 103.39M | 101.82M | 101.82M | 101.82M | 101.82M |
| Weighted Avg Shares Out (Dil) | 325.97M | 312.46M | 310.73M | 311.61M | 308.35M | 270.60M | 270.00M | 269.22M | 267.28M | 266.16M | 265.27M | 265.23M | 242.12M | 199.37M | 56.97M | 111.91M | 104.54M | 111.27M | 101.82M | 101.82M | 101.82M | 101.82M |
Source: https://incomestatements.info
Category: Stock Reports